12th IAS Conference on HIV Science (IAS 2023): further reports
1 October 2023. Related: Conference reports.
IAS 2023 Brisbane
IAS 2023: Lenacapavir studies at IAS: weekly oral dosing and baseline sensitivity in non-clade B settings
1 October 2023. Related: Conference reports, Antiretrovirals.
IAS 2023: LA-CAB/RPV as first-line ART and implementation studies
1 October 2023. Related: Conference reports, Antiretrovirals.
IAS 2023: bNAbs for prevention and cure: antiviral and vaccine-like responses
1 October 2023. Related: Conference reports, Antiretrovirals, HIV prevention and transmission, Cure-related research, Vaccines and microbicides.
IAS 2023: High rates of re-suppression with dolutegravir in the ADVANCE study
1 October 2023. Related: Conference reports, Treatment strategies, Drug resistance.
IAS 2023: In-utero tenofovir-based PrEP has no effect on children’s bone mineral density
1 October 2023. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.
12th IAS Conference on HIV Science (IAS 2023): further reports
1 September 2023. Related: Conference reports.
IAS 2023: Update to navigating the programme and online access
1 September 2023. Related: Conference reports.
IAS 2023: Metabolic and weight changes using GLP-1 agonists in people living with HIV: need for more data
1 September 2023. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.
IAS 2023: Rapporteur summary Track A – basic science
1 September 2023. Related: Conference reports, Cure-related research, Basic science and immunology, Vaccines and microbicides.
IAS 2023: Rapporteur summary Track C – prevention
1 September 2023. Related: Conference reports, HIV prevention and transmission.
IAS 2023: Rapporteur summary Track D – social and behavioural science
1 September 2023. Related: Conference reports, Treatment strategies.
12th IAS Conference on HIV Science (IAS 2023)
1 August 2023. Related: Conference reports.
IAS 2023: Update to navigate the programme and online access
1 August 2023. Related: Conference reports.
WHO endorses “zero” transmission risk for people with HIV with an undetectable viral load
1 August 2023. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
Viral load level when suppressed <1000 predicts future rebound: 3-monthly monitoring required
1 August 2023. Related: Conference reports, HIV prevention and transmission.
ART-associated hypertension can be successfully treated in African settings
1 August 2023. Related: Conference reports, Side effects, Coinfections and complications.
REPRIEVE study: statin benefits people living with HIV at low to moderate CVD risk
1 August 2023. Related: Conference reports, Coinfections and complications.
Geneva patient and other HIV cure research at IAS 2023
1 August 2023. Related: Conference reports, Cure-related research.
Guide to other HIV cure-related research at IAS 2023
1 August 2023. Related: Conference reports.
Rapporteur summaries: track B clinical science
1 August 2023. Related: Conference reports, Antiretrovirals.
Early press conference: cure, gay circumcision, PrEP choices, mpox, and COVID-19
1 August 2023. Related: Conference reports, mpox, HIV prevention and transmission, Cure-related research, COVID-19: HIV and COVID-19 coinfection, COVID-19.